Back to Resource Hub White paper

Takeaways and Perspectives: FDA Draft Guidance on DCTs

The FDA released draft guidance on decentralized clinical trials (DCTs) in May 2023.

Our clinical science and trial optimization experts reviewed the guidance and provide a summary of its key themes as well as offer their perspectives in this white paper.

eCOA
EDC
Electronic Clinician Ratings
Rater Training and Qualification
Unified eClinical Platform
CDR System
Sensors and Wearables

You’ll learn about applications for technology in DCTs, considerations for investigator oversight, and preserving data precision and integrity.

Read the paper to find out how this guidance might inform your next study.

Clinical Data Collection

Clinical IP Management

Patient Engagement

Clinical Data and Analytics

Clinical Consulting

Applications For

Takeaways and Perspectives: FDA Draft Guidance on DCTs

Similar posts

DHTs in Clinical Trials: Key Points From the FDA's Draft Guidance

Capturing Oncology Patients' PRO Data: Key Insights

A Review of EMA Recommendations on Decentralized Clinical Trial Elements

Looking for more insights? Explore related resources.

Signant’s Rapid eConsent Implementation Contributes to the Advancement of DCTs in Japan

eCOA and the DCT Slope of Enlightenment

Decentralized Clinical Trial Solutions

Get notified on new marketing insights